Brian Leyland-Jones

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. ncbi Trastuzumab: hopes and realities
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Quebec Canada
    Lancet Oncol 3:137-44. 2002
  2. ncbi Treating cancer-related hypercalcemia with gallium nitrate
    Brian Leyland-Jones
    Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec, Canada
    J Support Oncol 2:509-16. 2004
  3. ncbi Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study
    Brian Leyland-Jones
    Department of Medical Oncology, McGill University, 546 Pine Avenue W, Montreal, Quebec, Canada H2W 1S6
    J Clin Oncol 23:5960-72. 2005
  4. ncbi Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    J Clin Oncol 21:3965-71. 2003
  5. ncbi Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models
    Nezha Alami
    Oncology Department, McGill University, Montreal, QC, Canada
    Growth Horm IGF Res 18:487-96. 2008
  6. ncbi Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo
    Lori Jerome
    Department of Oncology, McGill University, West, Montreal, Quebec, Canada
    Cancer Res 66:7245-52. 2006
  7. ncbi Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay
    Mark Abramovitz
    VM Institute of Research, Montreal, Quebec, Canada
    Biotechniques 44:417-23. 2008
  8. ncbi Treatment of cancer-related hypercalcemia: the role of gallium nitrate
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Semin Oncol 30:13-9. 2003
  9. ncbi Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Canada
    Semin Oncol 30:174-84. 2003
  10. ncbi Identification of N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-5-carboxamide as components in urine extracts of individuals consuming coffee
    Pierre Wong
    Department of Oncology, McGill University, McIntyre Medical Science Bldg, Suite 701, 3655 Promenade Sir William Osler, Montreal, Quebec, Canada H3G 1Y6
    J Pharm Biomed Anal 30:773-80. 2002

Collaborators

Detail Information

Publications22

  1. ncbi Trastuzumab: hopes and realities
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Quebec Canada
    Lancet Oncol 3:137-44. 2002
    ..Trastuzumab is likely to find its ultimate role in the adjuvant setting. Its development provides a model for the integration of other gene-targeted therapies into breast-cancer management to improve survival and quality of life...
  2. ncbi Treating cancer-related hypercalcemia with gallium nitrate
    Brian Leyland-Jones
    Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec, Canada
    J Support Oncol 2:509-16. 2004
    ..Gallium nitrate is an effective treatment option for moderate-to-severe cancer-related hypercalcemia, a setting in which morbidity and mortality are high...
  3. ncbi Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study
    Brian Leyland-Jones
    Department of Medical Oncology, McGill University, 546 Pine Avenue W, Montreal, Quebec, Canada H2W 1S6
    J Clin Oncol 23:5960-72. 2005
    ..To evaluate the effect on survival and quality of life of maintaining hemoglobin (Hb) in the range of 12 to 14 g/dL with epoetin alfa versus placebo in women with metastatic breast cancer (MBC) receiving first-line chemotherapy...
  4. ncbi Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    J Clin Oncol 21:3965-71. 2003
    ..This phase II study evaluated the pharmacokinetics and safety of trastuzumab and paclitaxel given every 3 weeks to women with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic breast cancer...
  5. ncbi Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models
    Nezha Alami
    Oncology Department, McGill University, Montreal, QC, Canada
    Growth Horm IGF Res 18:487-96. 2008
    ..The effects of the different treatments on IGF-IR signaling pathways were also examined...
  6. ncbi Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo
    Lori Jerome
    Department of Oncology, McGill University, West, Montreal, Quebec, Canada
    Cancer Res 66:7245-52. 2006
    ..These results emphasize the merit of evaluating simultaneous blockade of the HER-2 and IGF-IR pathways using combination therapy with rhIGFBP-3 plus Herceptin in human clinical trials of patients with HER-2-positive breast cancer...
  7. ncbi Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay
    Mark Abramovitz
    VM Institute of Research, Montreal, Quebec, Canada
    Biotechniques 44:417-23. 2008
    ....
  8. ncbi Treatment of cancer-related hypercalcemia: the role of gallium nitrate
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Semin Oncol 30:13-9. 2003
    ..Importantly, unlike bisphosphonates, gallium nitrate is effective in both parathyroid-related protein-mediated and non-parathyroid-related protein-mediated hypercalcemia...
  9. ncbi Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Canada
    Semin Oncol 30:174-84. 2003
    ..The enhanced quality of life seen with erythropoietin treatment may also involve a modulation of hypoxia-induced decrement in cognitive functioning. It appears that epoetin alfa is a useful addition to the treatment of breast cancer...
  10. ncbi Identification of N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-5-carboxamide as components in urine extracts of individuals consuming coffee
    Pierre Wong
    Department of Oncology, McGill University, McIntyre Medical Science Bldg, Suite 701, 3655 Promenade Sir William Osler, Montreal, Quebec, Canada H3G 1Y6
    J Pharm Biomed Anal 30:773-80. 2002
    ..The findings are briefly discussed in relation to the nutritional sources of niacin and to current procedures for measuring amounts of the two metabolites in urine samples...
  11. ncbi Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine
    Pierre Wong
    Department of Oncology, McGill University, McIntyre Medical Science Building, Suite 701, 3655 Promenade Sir William Osler, Montreal, Quebec, Canada H3G 1Y6
    J Pharm Biomed Anal 28:693-700. 2002
    ..The results are discussed in relation to the mechanism of deformylation and the use of caffeine as a probe drug for NAT2 phenotyping...
  12. ncbi Proteomics: new technologies and clinical applications
    Martin Latterich
    Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada
    Eur J Cancer 44:2737-41. 2008
    ....
  13. ncbi Breast cancer trial with erythropoietin terminated unexpectedly
    Brian Leyland-Jones
    McGill University, Montreal, Canada
    Lancet Oncol 4:459-60. 2003
  14. ncbi Evidence for erythropoietin as a molecular targeting agent
    Brian Leyland-Jones
    Department of Oncology, McGill University, Montreal, Canada
    Semin Oncol 29:145-54. 2002
    ....
  15. ncbi Anti-insulin-like growth factor strategies in breast cancer
    Lori Jerome
    Department of Oncology, McGill University, Montreal, Quebec, Canada
    Semin Oncol 31:54-63. 2004
    ....
  16. ncbi Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment
    Mark Abramovitz
    VM Institute of Research, Montreal, Quebec, Canada
    Cancer Genomics Proteomics 4:135-45. 2007
    ..Application of these technologies to our understanding of breast cancer will undoubtedly have an impact on the individualization of treatment for breast cancer patients in the not to distant future...
  17. ncbi Optimizing treatment of HER2-positive metastatic breast cancer
    Alison L Jones
    Royal Free Hospital, London, UK
    Semin Oncol 31:29-34. 2004
    ..This has similar efficacy, tolerability, and pharmacokinetics (exposure) to the weekly regimen, providing a convenient schedule...
  18. ncbi Epoetin alfa: future directions and future research
    Heinz Ludwig
    Department of Medicine and Medical Oncology, Wilhelminenspital, Montleartstrasse 37, A-1171 Vienna, Austria
    Oncologist 9:70-3. 2004
  19. ncbi Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer
    Nicholas Robert
    US Oncology Research Inc, Houston, TX, USA
    J Clin Oncol 24:2786-92. 2006
    ..This randomized, multicenter, phase III trial evaluated the efficacy and safety of trastuzumab and paclitaxel with or without carboplatin as first-line therapy for women with HER-2-overexpressing metastatic breast cancer (MBC)...
  20. ncbi Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institute, Blvd de Waterloo 125, 1000 Brussels, Belgium
    N Engl J Med 353:1659-72. 2005
    ..We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy...
  21. ncbi Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer
    Angelika M Burger
    Laboratory of Molecular Pathology, Department of Anatomic Pathology and Division of Molecular and Cellular Biology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ont, Canada
    Eur J Cancer 41:1515-27. 2005
    ..In this review, we have examined the roles of IGFBP-3 and IGFBP-rP1 in breast cancer, and discuss the potential impact of these two proteins in mammary carcinoma risk assessment and the development of treatments for breast cancer...
  22. ncbi Erythropoietin to treat anaemia in patients with head and neck cancer
    Brian Leyland-Jones
    Lancet 363:80; author reply 81-2. 2004